Corcept Therapeutics Inc. (CORT)
NASDAQ:CORT
CORT Stock Chart & Stats
$41.91
$0.08(0.16%)
At close: 4:00 PM EST
$41.91
$0.08(0.16%)
Day’s Range― - ―
52-Week Range$28.66 - $91.00
Previous CloseN/A
Volume78.39K
Average Volume (3M)1.71M
Market Cap
$4.46B
Enterprise Value$4.34B
Total Cash (Recent Filing)$372.15M
Total Debt (Recent Filing)$6.11M
Price to Earnings (P/E)36.3
Beta0.45
Next Earnings
May 06, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.20
Shares Outstanding106,374,020
10 Day Avg. Volume1,239,825
30 Day Avg. Volume1,705,208
Financial Highlights & Ratios
PEG Ratio-1.22
Price to Book (P/B)5.58
Price to Sales (P/S)4.75
P/FCF Ratio25.49
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue5.70
Enterprise Value/Gross Profit5.80
Enterprise Value/Ebitda76.03
Forecast
1Y Price Target
$81.00Price Target Upside93.27% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.38
Revenue Forecast (FY)$899.55M
Bulls Say, Bears Say
Bulls Say
Clinical Evidence CommunicationA full ROSELLA study presentation with complete efficacy, safety, and subgroup analyses will provide clinicians and payers with detailed data to inform adoption and reimbursement discussions.
Commercial ReadinessManagement's plan for a dedicated oncology sales force supports commercial launch capacity and could accelerate relacorilant uptake in oncology markets.
Regulatory ApprovalRegulatory approval of relacorilant for certain women's cancers validates cortisol modulation as an effective treatment mechanism and establishes the company's first commercial oncology product, supporting business diversification.
Bears Say
Generic Competition And Legal RiskA court ruling that reduces the ability to block generic entrants combined with strong uptake of an authorized generic increases the risk of price erosion and market share loss for the branded franchise.
Product Concentration RiskKorlym is the company's only revenue-generating product, leaving the company heavily dependent on its commercial performance and vulnerable to demand or pricing shocks.
Supply Chain And DistributionRepeated distribution failures and specialty pharmacy capacity constraints disrupted prescription fulfillment and could continue to constrain Korlym sales unless supply channels fully stabilize.
Corcept Therapeutics News
CORT FAQ
What was Corcept Therapeutics Inc.’s price range in the past 12 months?
Corcept Therapeutics Inc. lowest stock price was $28.66 and its highest was $91.00 in the past 12 months.
What is Corcept Therapeutics Inc.’s market cap?
Corcept Therapeutics Inc.’s market cap is $4.46B.
When is Corcept Therapeutics Inc.’s upcoming earnings report date?
Corcept Therapeutics Inc.’s upcoming earnings report date is May 06, 2026 which is in 24 days.
How were Corcept Therapeutics Inc.’s earnings last quarter?
Corcept Therapeutics Inc. released its earnings results on Feb 24, 2026. The company reported $0.2 earnings per share for the quarter, missing the consensus estimate of $0.329 by -$0.129.
Is Corcept Therapeutics Inc. overvalued?
According to Wall Street analysts Corcept Therapeutics Inc.’s price is currently Undervalued.
Does Corcept Therapeutics Inc. pay dividends?
Corcept Therapeutics Inc. does not currently pay dividends.
What is Corcept Therapeutics Inc.’s EPS estimate?
Corcept Therapeutics Inc.’s EPS estimate is -0.11.
How many shares outstanding does Corcept Therapeutics Inc. have?
Corcept Therapeutics Inc. has 106,374,020 shares outstanding.
What happened to Corcept Therapeutics Inc.’s price movement after its last earnings report?
Corcept Therapeutics Inc. reported an EPS of $0.2 in its last earnings report, missing expectations of $0.329. Following the earnings report the stock price went down -0.713%.
Which hedge fund is a major shareholder of Corcept Therapeutics Inc.?
Currently, no hedge funds are holding shares in CORT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Corcept Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$81.00 (93.27% Upside)
$81.00 (93.27% Upside)
Blogger Sentiment
Bullish
CORT Sentiment 83%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 559.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $3.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.1%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-38.12%
12-Months-Change
Fundamentals
Return on Equity
15.25%
Trailing 12-Months
Asset Growth
-0.30%
Trailing 12-Months
Company Description
Corcept Therapeutics Inc.
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.
CORT Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mix of strong commercial momentum, robust clinical successes across multiple programs (notably ROSELLA and DAZALS), clear revenue growth and higher guidance, and resolved operational capacity with an improving commercial outlook. These positives are tempered by a significant regulatory setback for relacorilant in Cushing's syndrome, a Federal Circuit loss in the generic patent dispute, meaningful net income decline, and prior pharmacy-related supply disruptions. The pipeline and upcoming readouts provide multiple near-term catalysts, while regulatory and legal risks require attention.View all CORT earnings summariesCORT Stock 12 Month Forecast
Average Price Target
$81.00
▲(93.27% Upside)
Technical Analysis
Jazz Pharmaceuticals
―
Axsome Therapeutics
―
Rhythm Pharmaceuticals
―
Revolution Medicines
―
Legend Biotech
―
Ownership Overview
11.76% Insiders
18.73% Mutual Funds
14.95% Other Institutional Investors
32.11% Public Companies and
Individual Investors